Fast and Longest Rollercoasters

For k >= 3, a k-rollercoaster is a sequence of numbers whose every maximal contiguous subsequence, that is increasing or decreasing, has length at least k; 3-rollercoasters are called simply rollercoasters. Given a sequence of distinct real numbers, we are interested in computing its maximum-length (not necessarily contiguous) subsequence that is a k-rollercoaster. Biedl et al. (2018) have shown that each sequence of n distinct real numbers contains a rollercoaster of length at least ceil[n/2] for n>7, and that a longest rollercoaster contained in such a sequence can be computed in O(n log n)-time (or faster, in O(n log log n) time, when the input sequence is a permutation of {1,...,n}). They have also shown that every sequence of n >=slant (k-1)^2+1 distinct real numbers contains a k-rollercoaster of length at least n/(2(k-1)) - 3k/2, and gave an O(nk log n)-time (respectively, O(n k log log n)-time) algorithm computing a longest k-rollercoaster in a sequence of length n (respectively, a permutation of {1,...,n}). In this paper, we give an O(nk^2)-time algorithm computing the length of a longest k-rollercoaster contained in a sequence of n distinct real numbers; hence, for constant k, our algorithm computes the length of a longest k-rollercoaster in optimal linear time. The algorithm can be easily adapted to output the respective k-rollercoaster. In particular, this improves the results of Biedl et al. (2018), by showing that a longest rollercoaster can be computed in optimal linear time. We also present an algorithm computing the length of a longest k-rollercoaster in O(n log^2 n)-time, that is, subquadratic even for large values of k <= n. Again, the rollercoaster can be easily retrieved. Finally, we show an Omega(n log k) lower bound for the number of comparisons in any comparison-based algorithm computing the length of a longest k-rollercoaster

Antipsychotic Drugs Efficacy in Dextromethorphan-Induced Psychosis

Psychosis is known as a broad term of symptoms that cause serious disorganization of behavior, thinking, and perception of reality. One of the medicines that recently gained much attention in terms of its psychotic potential is dextromethorphan (DXM). DXM, a widely used antitussive drug, is a commonly abused drug because of its euphoric, hallucinogenic, and dissociative properties. To date, DXM is a legally marketed cough suppressant that is neither a controlled substance nor a regulated chemical under the Controlled Substances Act. The management of DXM-related psychosis is dependent on the type of psychotic symptoms. Atypical neuroleptics (i.e., olanzapine, risperidone, quetiapine) and typical haloperidol have been used in symptomatic treatment due to their efficacy, especially in positive symptoms (hallucinations and delusions). These agents are also recognized as the preferred option in the symptomatic treatment of DXM-related psychosis due to their better efficacy and safety profile than typical haloperidol in the short-term course. The focus of the present review concerns the current stage of knowledge about DXM psychotic potency as well as the management of DXM-related psychoses with a special emphasis on atypical antipsychotic drugs (i.e., olanzapine, risperidone, quetiapine, and haloperidol)

4-Pyridone-3-carboxamide-1-&beta;-D-ribonucleoside (4PYR)&mdash;A Novel Oncometabolite Modulating Cancer-Endothelial Interactions in Breast Cancer Metastasis

The accumulation of specific metabolic intermediates is known to promote cancer progression. We analyzed the role of 4-pyridone-3-carboxamide-1-&beta;-D-ribonucleoside (4PYR), a nucleotide metabolite that accumulates in the blood of cancer patients, using the 4T1 murine in vivo breast cancer model, and cultured cancer (4T1) and endothelial cells (ECs) for in vitro studies. In vivo studies demonstrated that 4PYR facilitated lung metastasis without affecting primary tumor growth. In vitro studies demonstrated that 4PYR affected extracellular adenine nucleotide metabolism and the intracellular energy status in ECs, shifting catabolite patterns toward the accumulation of extracellular inosine, and leading to the increased permeability of lung ECs. These changes prevailed over the direct effect of 4PYR on 4T1 cells that reduced their invasive potential through 4PYR-induced modulation of the CD73-adenosine axis. We conclude that 4PYR is an oncometabolite that affects later stages of the metastatic cascade by acting specifically through the regulation of EC permeability and metabolic controls of inflammation